Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-14. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Ongoing patent litigation against UTHR determines Liquidia's commercial exclusivity and revenue multiple for Yutrepia in pulmonary arterial hypertension.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factLiquidia's lead drug Yutrepia reached over 5,000 patients on therapy as of July 2026. |
| What else was confirmed? | Reported factLiquidia shares declined 13.9% over the past month. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for LQDA yet — this is the next research task. |
| What would change the assessment? | UnknownFederal court patent docket entries on Yutrepia — District and appellate court rulings regarding United Therapeutics patent enforceability. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Liquidia's lead drug Yutrepia reached over 5,000 patients on therapy as of July 2026.
- · Liquidia shares declined 13.9% over the past month.
- · The company faces active patent litigation and competitive market pressure from United Therapeutics.
- · Liquidia operates with single-product concentration and rising research and development expenses.
Public research record
Research framework · page evidenceCompleted event assessment
patent litigation outcome and commercial adoption
| Type | Claim | Scope |
|---|---|---|
| Assumption | Liquidia's lead drug Yutrepia reached over 5,000 patients on therapy as of July 2026. | 2026-09-14 |
| Interpretation | patent litigation outcome and commercial adoption | LQDA |
Countercase, invalidators, and sources
Favorable patent court rulings eliminate injunction risks, accelerating Yutrepia adoption past commercial guidance targets.
- · Federal court patent docket entries on Yutrepia — District and appellate court rulings regarding United Therapeutics patent enforceability.
- LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? · 2026-09-11
What remains unresolved
- Base path
- Patient starts expand steadily while legal proceedings extend without immediate market-exclusivity injunctions.
- Adverse path
- Adverse appellate or district court patent ruling restricts Yutrepia marketing, triggering severe top-line compression.
- Supportive path
- Favorable patent court rulings eliminate injunction risks, accelerating Yutrepia adoption past commercial guidance targets.
- · Federal court patent docket entries on Yutrepia — District and appellate court rulings regarding United Therapeutics patent enforceability.this week
Evidence
- LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?2026-09-11
“Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics...”
Supports: Yutrepia reached over 5,000 patients, LQDA fell 13.9% over a month, and patent litigation with UTHR continues.